Bioasis Technologies reveals research validating its blood brain barrier deliver platform to improve neurological function

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) announced the publication of research validating the ability of the company’s xB³ platform to efficiently deliver small interfering RNA (siRNA) across the blood-brain barrier to the central nervous system in therapeutically relevant doses.

Bioasis said the research shows that the xB³ platform can act as a delivery vector to facilitate blood-brain barrier (BBB) translocation of siRNA, reducing stroke damage in the brain and improved neurological function.  

“The results from this research collaboration further validates the utility of our xB³ platform technology to achieve delivery of therapeutic compounds including siRNA across the BBB at levels that may help treat a variety of central nervous system diseases,” Bioasis Technologies executive chair Dr Deborah Rathjen said in a statement.

READ: Bioasis has the best platform technology for shuttling drugs across the blood-brain barrier

“This data is consistent with the previous studies where our technology successfully delivered antibodies and enzymes across the BBB with demonstrated efficacy in both the brain and the periphery in settings as diverse as brain cancers, neuropathic pain and lysosomal storage disorders,”  Dr. Rathjen added.

University of British Columbia Professor Dr. Wilfred Jefferies also commented, stating: “This study demonstrates for the first time, the translocation of a small peptide, nanomule, across the intact blood brain barrier carrying a payload sufficient to modify a disease in the central nervous system, in this case a siRNA that ameliorates ischemic stroke.”

“The implications of this discovery are wide ranging, and this platform may provide a general method to intervene in diseases of the brain.”

The research conducted by Eyford, et al., “A Nanomule Peptide Carrier Delivers siRNA Across the Intact Blood-Brain Barrier to Attenuate Ischemic Stroke,” was published in the Frontiers in Molecular Biosciences.

The company said the data presented in the publication provide evidence for the utility of xB³ peptide (previously known as MTfpep) as a platform technology for delivery of recombinant and chemically conjugated drug across the BBB.

It added the study demonstrates both siRNA-carrier delivery and therapeutic efficacy in central nervous system disease model where the BBB remains intact and thus offers new avenues for potential siRNA focused treatments in variety of neuropathologies that are currently resistant to existing therapies.

Scientists at Bioasis have worked for over a decade to develop the patented xB³ platform, which helps small molecules shuttle across the BBB safely. Like a key designed to open a lock, the xB³ platform unlocks the door to the blood-brain barrier, allowing compounds into the brain. In a nutshell, the xB³ platform uses a small peptide to ferry molecules across the BBB in a process called receptor-mediated transcytosis.

Contact Sean at [email protected]

Story by ProactiveInvestors